US Stock MarketDetailed Quotes

ALGS Aligos Therapeutics

Watchlist

0.500
-0.008-1.59%

Close Jun 14 16:00 ET

39.05MMarket Cap-476P/E (TTM)

Aligos Therapeutics Stock Forum

Jaguar8

May 21 07:05

$Aligos Therapeutics(ALGS.US)$
NEWS
Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH
Aligos Therapeutics (Nasdaq: ALGS) has completed enrollment for its Phase 2a HERALD study of ALG-055009, targeting metabolic dysfunction-associated steatohepatitis (MASH). The study enrolled around 100 subjects with liver fibrosis. Topline safety and efficacy data are expected in early Q4 2024.
Dr. Rohit Loomba, a renowned expert in gast...

Trytosaveabit

Apr 25 15:08

Update

$Aligos Therapeutics(ALGS.US)$ Aligos Therapeutics Presents Positive Clinical Data at Escmid 2024 From the Alg-097558 Phase 1 Study

Jaguar8

Apr 25 15:06

$Aligos Therapeutics(ALGS.US)$
NEWS
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
The data shows that the pan-coronavirus protease inhibitor ALG-097558 was well tolerated and does not require ritonavir boosting.
The PK profile supports twice daily ritonavir-free dosing without a food effect.
Aligos has developed a robust clinical pipeline of three potentially best-in-class drug candidates.
The presentation highlights the best-in-class potent...

Trytosaveabit

Apr 2 08:03

Update

$Aligos Therapeutics(ALGS.US)$ Mirum’s LIVMARLI receives positive reimbursement recommendation by Canada’s CADTH

Moomoo AI

Mar 6 14:13

Aligos Therapeutics' P/S ratio remains below industry median due to poor revenue outlook. Without significant change, a drastic stock price rise is unlikely. The low P/S ratio is justified by inferior revenue forecasts.

Aligos Therapeutics, Inc.'s (NASDAQ:ALGS) Share Price Boosted 45% But Its Business Prospects Need A Lift Too

Moomoo AI

Feb 13 07:06

The company anticipates the new appointments to be beneficial as they advance towards significant clinical data and strategically expand their team for Aligos' next growth phase. Both Tarazi and Aneja are thrilled to contribute to Aligos' mission in treating liver and viral diseases.